These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 37005519)

  • 1. Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson's Disease Patients.
    Ciocca M; Pizzamiglio C
    CNS Neurol Disord Drug Targets; 2024; 23(5):554-561. PubMed ID: 37005519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons.
    Kim GJ; Mo H; Liu H; Wu Z; Chen S; Zheng J; Zhao X; Nucum D; Shortland J; Peng L; Elepano M; Tang B; Olson S; Paras N; Li H; Renslo AR; Arkin MR; Huang B; Lu B; Sirota M; Guo S
    Elife; 2021 Sep; 10():. PubMed ID: 34550070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson's Disease.
    Das NR; Sharma SS
    CNS Neurol Disord Drug Targets; 2015; 14(8):1024-30. PubMed ID: 25808897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial Dysfunction in Parkinson's Disease: New Mechanistic Insights and Therapeutic Perspectives.
    Park JS; Davis RL; Sue CM
    Curr Neurol Neurosci Rep; 2018 Apr; 18(5):21. PubMed ID: 29616350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ghrelin mediated neuroprotection - A possible therapy for Parkinson's disease?
    Morgan AH; Rees DJ; Andrews ZB; Davies JS
    Neuropharmacology; 2018 Jul; 136(Pt B):317-326. PubMed ID: 29277488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondria: prospective targets for neuroprotection in Parkinson's disease.
    Yadav A; Agarwal S; Tiwari SK; Chaturvedi RK
    Curr Pharm Des; 2014; 20(35):5558-73. PubMed ID: 24606805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological therapy in Parkinson's disease: focus on neuroprotection.
    Kincses ZT; Vecsei L
    CNS Neurosci Ther; 2011 Oct; 17(5):345-67. PubMed ID: 20438581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Coenzyme Q10 in Parkinson's disease. Symptomatic or neuroprotective effects?].
    Storch A
    Nervenarzt; 2007 Dec; 78(12):1378-82. PubMed ID: 17508194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.
    Jin H; Kanthasamy A; Ghosh A; Anantharam V; Kalyanaraman B; Kanthasamy AG
    Biochim Biophys Acta; 2014 Aug; 1842(8):1282-94. PubMed ID: 24060637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of neuroprotection for Parkinson's disease.
    LeWitt PA
    Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
    [No Abstract]   [Full Text] [Related]  

  • 12. Modulation of endoplasmic reticulum stress in Parkinson's disease.
    Tsujii S; Ishisaka M; Hara H
    Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
    Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective therapy for Parkinson's disease.
    Koller WC
    Exp Neurol; 1997 Mar; 144(1):24-8. PubMed ID: 9126147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Flavonoids against Parkinson's Disease.
    Varshney H; Siddique YH
    Cent Nerv Syst Agents Med Chem; 2024; 24(2):145-165. PubMed ID: 38305395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targets for neuroprotection in Parkinson's disease.
    Yacoubian TA; Standaert DG
    Biochim Biophys Acta; 2009 Jul; 1792(7):676-87. PubMed ID: 18930814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progression.
    Pienaar IS; Chinnery PF
    Pharmacol Ther; 2013 Jan; 137(1):1-21. PubMed ID: 22960453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free-radical toxicity and antioxidant medications in Parkinson's disease.
    Ciccone CD
    Phys Ther; 1998 Mar; 78(3):313-9. PubMed ID: 9520976
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting mitochondria for neuroprotection in Parkinson's disease.
    Schapira AH
    Antioxid Redox Signal; 2012 May; 16(9):965-73. PubMed ID: 22229791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.